bone metabolism; secondary hyperparathyroidism; phosphate binders; phosphorus metabolism disorders; hemodialyzed patients; anomalies du bilan phosphocalcique; patients dialysés; métabolisme osseux; hyperparathyroïdie secondaire; chélateurs du phosphore
Abstract :
[en] Bone metabolism is very frequently disturbed in end stage renal failure hemodialyzed, with secondary hyperparathyroidism development but also serious potential cardiovascular consequences. New treatments will be available very soon in Europe such as new phosphate binders, vitamin D2 analogues or calcimimetics to fight against such medical diseases, with the hope of less risk for vascular complications. The real place of such new medical opportunities needs to be determined. Moreover, studies with morbidity and mortality end-points are waited before estimating the real importance of these new therapeutic tools. [fr] Les désordres du métabolisme phosphocalcique sont fréquents, difficiles à corriger et ont une influence négative sur la santé osseuse (hyperparathyroïdie secondaire) mais aussi celle cardiovasculaire des patients dialysés. De nouveaux chélateurs du phosphore, des analogues de la vitamine D et des calcimimétiques se profilent dans notre arsenal thérapeutique européen contre l'hyperparathyroïdie secondaire, avec l'espoir de réduire en plus le risque de calcifications vasculiares. Leur place respective dans la séquence d'évolution des troubles phosphocalciques au stade de la dialyse reste cependant à définir. Des études de morbidité et mortalité sont aussi attendues afin d'estimer le réel avantage de ces moyens thérapeutiques.
Disciplines :
Urology & nephrology
Author, co-author :
Van Overmeire, Lionel ; Centre Hospitalier Universitaire de Liège - CHU > Frais communs médecine
Delanaye, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Néphrologie
Krzesinski, Jean-Marie ; Université de Liège - ULiège > Département des sciences cliniques > Néphrologie
Language :
French
Title :
Nouveautés dans la prise en charge médicale des anomalies du bilan phosphocalcique chez le patient hémodialysé
Alternative titles :
[en] News in the Management of Calcium and Phosphorus Metabolism Disorders for Patient Treated by Hemodialysis
Goodman WG. Medical management of secondary hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant 2003;18(Suppl.):S2-S8.
Oprisiu R, Hottelart C, Ghitsu S, et al. Ostéodystrophie rénale (1); diagnostic invasif et non invasif des variétés histopathologiques. Néphrologie 2000;21:229-37.
Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998;31:607-17.
Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-8.
Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18.
Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: The dialysis outcomes and practice patterns study. Kidney Int 2005;67:1179-87.
Goodman WG. Importance of hyperphosphataemia in the cardio-renal axis. Nephrol Dial Transplant 2004;19(Suppl.):i4-i8.
Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;332:1478-83.
Emmet M. A comparison of clinical useful phosphorus binders for patients with chronic kidney failure. Kidney Int 2004;66(Suppl.):S25-S32.
K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 2003;42(Suppl.):S1-S255.
Sadek T, Mazouz H, Bahloul H, et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: An open-label, randomized study. Nephrol Dial Transplant 2003;18:582-9.
Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52.
Chertow GM, Burke SK, Dillon MA et al. Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999;14:2907-14.
Chertow GM, Raggi P, McCarthy J, et al. The effects of sevelamer and calcium acetate on proxies of atherosclerosis and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 2003;23:307-14.
Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in hemodialysis patients: The calcium acetate renagel evaluation (CARE Study). Kidney Int 2004;65:1914-26.
Hutchinson AJ, Maes B, Vanwalleghem J, et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: A 6-month, randomized, comparative trial versus calcium carbonate. Nephron 2005;100:c8-c19.
Behets GJ, Dams G, Vercauteren SV, et al. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol 2004;15:2219-28.
Lacour B, Lucas A, Auchère D, et al. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 2005;67:1062-9.
Yang WC, Yang CS, Hou CC, et al. An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: Ferric citrate. Nephrol Dial Transplant 2002;17:265-70.
Takahashi Y, Tanaka A, Nakamura T, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 2004;65:1099-104.
Malluche HH, Mawad H, Koszewski NJ. Update on vitamine D and its newer analogues: Actions and rationale for treatment in chronic renal failure. Kidney Int 2002;62:367-74.
Brandi L, Egfjord M, Olgaard K. Comparison between 1a (OH)D3 and 1,25 (OH)2D3 on the suppression of plasma PTH levels in uremic patients, evaluated by the «whole» and «intact» PTH assays. Nephron 2005;99:C128-C37.
Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56.
Block GA, Martin KJ, de Francisco ALM, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25.
Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQITM bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005;67:760-71.
Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, muticenter study. J Am Soc Nephrol 2005;16:800-7.
Shahapuni I, Mansour J, Harbouche L, et al. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients? Seminars in Dialysis 2005;18:226-38.
Cunningham J. Achieving therapeutic targets in the treatment of secondary hyperparathyroidism. Nephrol Dial Transplant 2004;19(Suppl.):v9-v14.
